14 research outputs found
A tribute to Elizaveta Ubryatova: professional life and personal destiny
The article was submitted on 10.06.2015. Translated by Dr. Lilia Gorelova.In Russia, the name of prominent turkologist Elizaveta Ivanovna Ubryatova, at present is known mostly to specialists who study the languages spoken by the Northern peoples of the country. However, the essence of scientific research of a linguist of such a calibre includes naturally attentive and concerned attitude to the fate of the peoples residing in the North of Russia, which was especially important in the conditions of the Soviet era. Survival of the Northern peoples and their languages became for Ubryatova not only a scientific problem but also a mission of vital importance. Ubryatovaβs scientific interests were not restricted to linguistic problems, she also purposefully studied the important monuments of folk literature and ethnography of indigenous peoples. This was due to her scientific breadth, social responsibility, and commitment to a supreme mastery of the research object. That is why she became the founder of the original linguistic and cultural school in the study of the history and structures of languages spoken by peoples living in the North of Russia. The scale of her bright personality, combined with her intelligence, patience, and feminine care about colleagues and students, made her a center of attraction for researchers in this field. She launched an extensive project of publishing works devoted to folklore of the peoples who inhabited the Northern territories of Russia, and whose traditional culture became a part of the world culture as a result. The languages of the Dolgans and Yakuts became the main topics of her research. In this article, we outline the major ideas proposed by Ubryatova in her works, viz., those concerning the origin of the Turkic languages, Dolgan and Yakut in particular, and principles of the organization of the Yakut syntax. In her works, devoted to syntactic problems, Ubryatova determined the fundamental characteristic features of systemic organization of Turkic languages, Yakut in particular, as the ability of these languages to link language units of different levels between each other by using the same grammatical means. In Turkic languages, almost all syntactic relations between clauses can be expressed grammatically, and this linguistic phenomenon entails the existence of a diverse and advanced system of non-finite verbal forms. These important findings can be successfully generalised to embrace all Altaic languages. Addressing a linguistic problem, Ubryatova combined her deep intuition with intensive field work and systematic theoretic investigation. Monographs and textbooks written by Ubryatova belong to the gold reserve of Turkology and cultural linguistics.Π‘ΡΠ΅Π΄ΠΈ ΡΠΎΡΡΠΈΠΉΡΠΊΠΈΡ
Π»ΠΈΠ½Π³Π²ΠΈΡΡΠΎΠ² ΠΈΠΌΡ ΠΠ»ΠΈΠ·Π°Π²Π΅ΡΡ ΠΠ²Π°Π½ΠΎΠ²Π½Ρ Π£Π±ΡΡΡΠΎΠ²ΠΎΠΉ ΠΈΠ·Π²Π΅ΡΡΠ½ΠΎ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΡΠΏΠ΅ΡΠΈΠ°Π»ΠΈΡΡΠ°ΠΌ, ΠΈΠ·ΡΡΠ°ΡΡΠΈΠΌ ΡΠ·ΡΠΊΠΈ Π½Π°ΡΠΎΠ΄ΠΎΠ² Π‘Π΅Π²Π΅ΡΠ°. ΠΠ΄Π½Π°ΠΊΠΎ ΡΡΡΡ Π½Π°ΡΡΠ½ΡΡ
ΠΈΠ·ΡΡΠΊΠ°Π½ΠΈΠΉ Π»ΠΈΠ½Π³Π²ΠΈΡΡΠΎΠ² ΡΡΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ»Ρ Π·Π°ΠΊΠΎΠ½ΠΎΠΌΠ΅ΡΠ½ΠΎ Π²ΠΊΠ»ΡΡΠ°Π»Π° Π² ΡΠ΅Π±Ρ Π½Π΅ΡΠ°Π²Π½ΠΎΠ΄ΡΡΠ½ΠΎΠ΅ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΠΊ ΡΡΠ΄ΡΠ±Π΅ Π½Π°ΡΠΎΠ΄ΠΎΠ² Π‘Π΅Π²Π΅ΡΠ° Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΡΠΎΠ²Π΅ΡΡΠΊΠΎΠ³ΠΎ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ, ΡΡΠΎ Π΄Π»Ρ Π£Π±ΡΡΡΠΎΠ²ΠΎΠΉ Π±ΡΠ»ΠΎ Π½Π΅ ΡΠΎΠ»ΡΠΊΠΎ Π½Π°ΡΡΠ½ΠΎΠΉ, Π½ΠΎ ΠΈ ΠΆΠΈΠ·Π½Π΅Π½Π½ΠΎΠΉ Π·Π°Π΄Π°ΡΠ΅ΠΉ. ΠΠ»ΠΈΠ·Π°Π²Π΅ΡΠ° ΠΠ²Π°Π½ΠΎΠ²Π½Π°, ΠΏΡΡΡ ΠΊΠΎΡΠΎΡΠΎΠΉ ΠΎΡΡΠ°ΡΡΠΈ ΡΠ»ΡΡΠ°ΠΉΠ½ΠΎ ΠΏΠ΅ΡΠ΅ΡΠ΅ΠΊΡΡ Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ Π½Π΅ ΡΠΎΠ»ΡΠΊΠΎ ΡΠ·ΡΠΊΠ°, Π½ΠΎ ΠΈ ΠΏΠ°ΠΌΡΡΠ½ΠΈΠΊΠΎΠ² ΡΠΎΠ»ΡΠΊΠ»ΠΎΡΠ½ΠΎΠΉ ΡΠ»ΠΎΠ²Π΅ΡΠ½ΠΎΡΡΠΈ ΠΈ ΡΡΠ½ΠΎΠ³ΡΠ°ΡΠΈΠΈ, ΠΎΡΠ½ΡΠ΄Ρ Π½Π΅ ΡΠ»ΡΡΠ°ΠΉΠ½ΠΎ, Π° Π² ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ΅ Π½Π°ΡΡΠ½ΠΎΠΉ Π΄ΠΎΠ±ΡΠΎΡΠΎΠ²Π΅ΡΡΠ½ΠΎΡΡΠΈ ΠΈ ΡΡΡΠ΅ΠΌΠ»Π΅Π½ΠΈΡ ΠΊ Π΄ΠΎΡΠΊΠΎΠ½Π°Π»ΡΠ½ΠΎΠΌΡ Π·Π½Π°Π½ΠΈΡ ΠΎΠ±ΡΠ΅ΠΊΡΠ° ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΡΠ°Π½ΠΎΠ²ΠΈΡΡΡ ΠΎΡΠ½ΠΎΠ²Π°ΡΠ΅Π»Π΅ΠΌ ΠΎΡΠΈΠ³ΠΈΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ Π»ΠΈΠ½Π³Π²ΠΎΠΊΡΠ»ΡΡΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΡ Π² ΠΈΠ·ΡΡΠ΅Π½ΠΈΠΈ ΠΈΡΡΠΎΡΠΈΠΈ ΠΈ ΡΡΡΡΠΊΡΡΡΡ ΡΠ·ΡΠΊΠΎΠ² Π½Π°ΡΠΎΠ΄ΠΎΠ², ΠΆΠΈΠ²ΡΡΠΈΡ
Π½Π° ΡΠ΅Π²Π΅ΡΠ΅ Π ΠΎΡΡΠΈΠΈ. ΠΠ°ΡΡΡΠ°Π± Π»ΠΈΡΠ½ΠΎΡΡΠΈ, ΡΡΠΊΠ°Ρ ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡΠ°Π»ΡΠ½ΠΎΡΡΡ Π² ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠΈ Ρ Π½Π°ΡΡΠΎΡΡΠ΅ΠΉ ΠΈΠ½ΡΠ΅Π»Π»ΠΈΠ³Π΅Π½ΡΠ½ΠΎΡΡΡΡ, ΡΠ΅ΡΠΏΠ΅Π½ΠΈΠ΅ΠΌ ΠΈ ΠΆΠ΅Π½ΡΠΊΠΎΠΉ Π·Π°Π±ΠΎΡΠΎΠΉ ΠΎΠ± ΠΎΠΊΡΡΠΆΠ°ΡΡΠΈΡ
ΡΠΎΡΡΡΠ΄Π½ΠΈΠΊΠ°Ρ
ΠΈ ΡΡΠ΅Π½ΠΈΠΊΠ°Ρ
ΡΠ΄Π΅Π»Π°Π»ΠΈ Π΅Π΅ ΡΠ΅Π½ΡΡΠΎΠΌ ΠΏΡΠΈΡΡΠΆΠ΅Π½ΠΈΡ, ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ»ΠΈ ΡΡΠΎΡΠΌΠΈΡΠΎΠ²Π°ΡΡ ΡΠΊΠΎΠ»Ρ, Π·Π°ΠΏΠ»Π°Π½ΠΈΡΠΎΠ²Π°ΡΡ ΠΈ ΠΎΡΡΡΠ΅ΡΡΠ²ΠΈΡΡ Π²Π΅Π»ΠΈΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΠΉ ΠΏΡΠΎΠ΅ΠΊΡ ΠΈΠ·Π΄Π°Π½ΠΈΡ ΡΠΎΠ»ΡΠΊΠ»ΠΎΡΠ° Π½Π°ΡΠΎΠ΄ΠΎΠ² Π‘Π΅Π²Π΅ΡΠ°, Π³Π΄Π΅ ΡΠ°ΠΌΠΎΠ±ΡΡΠ½Π°Ρ ΠΊΡΠ»ΡΡΡΡΠ° ΡΡΠΎΠΉ ΡΠ΅ΡΡΠΈΡΠΎΡΠΈΠΈ ΡΡΠ°Π»Π° ΡΠ°ΡΡΡΡ ΠΌΠΈΡΠΎΠ²ΠΎΠΉ ΠΊΡΠ»ΡΡΡΡΡ. ΠΠ»Π°Π²Π½ΡΠΌΠΈ Π² Π΅Π΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΡΡΠ°Π»ΠΈ ΡΡΡΠΊΡΠΊΠΈΠ΅ ΡΠ·ΡΠΊΠΈ - Π΄ΠΎΠ»Π³Π°Π½ΡΠΊΠΈΠΉ ΠΈ ΡΠΊΡΡΡΠΊΠΈΠΉ. Π ΡΡΠ°ΡΡΠ΅ ΠΏΡΠΎΠΏΠΈΡΠ°Π½Ρ ΠΎΡΠ½ΠΎΠ²Π½ΡΠ΅ ΡΠ΅Π·ΠΈΡΡ ΡΠ°Π±ΠΎΡ Π£Π±ΡΡΡΠΎΠ²ΠΎΠΉ ΠΏΠΎ ΡΠ΅ΠΌΠ°ΠΌ Β«ΠΡΠΎΠΈΡΡ
ΠΎΠΆΠ΄Π΅Π½ΠΈΠ΅ ΡΡΡΠΊΡΠΊΠΈΡ
ΡΠ·ΡΠΊΠΎΠ²Β» ΠΈ Β«ΠΡΠΈΠ½ΡΠΈΠΏΡ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΈ ΡΠΈΠ½ΡΠ°ΠΊΡΠΈΡΠ° ΡΠΊΡΡΡΠΊΠΎΠ³ΠΎ ΡΠ·ΡΠΊΠ°Β». Π ΡΡΡΠ΄Π°Ρ
ΠΏΠΎ ΡΠΈΠ½ΡΠ°ΠΊΡΠΈΡΡ ΠΠ»ΠΈΠ·Π°Π²Π΅ΡΠ° Π£Π±ΡΡΡΠΎΠ²Π° ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ΅Ρ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΡ ΡΠΈΡΡΠ΅ΠΌΠ½ΠΎΠΉ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΈ ΡΡΡΠΊΡΠΊΠΈΡ
ΡΠ·ΡΠΊΠΎΠ², ΠΈ ΡΠΊΡΡΡΠΊΠΎΠ³ΠΎ Π² ΡΠ°ΡΡΠ½ΠΎΡΡΠΈ, ΠΊΠ°ΠΊ ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΡ Π΅Π΄ΠΈΠ½ΠΈΡ ΡΠ°Π·Π½ΠΎΠ³ΠΎ ΡΡΠΎΠ²Π½Ρ ΡΠΎΠ΅Π΄ΠΈΠ½ΡΡΡΡΡ ΠΏΡΠΈ ΠΏΠΎΠΌΠΎΡΠΈ ΠΎΠ΄Π½ΠΈΡ
ΠΈ ΡΠ΅Ρ
ΠΆΠ΅ ΡΡΠ΅Π΄ΡΡΠ². ΠΠ΄Π΅Ρ Π£Π±ΡΡΡΠΎΠ²ΠΎΠΉ ΠΎ ΡΠΎΠΌ, ΡΡΠΎ ΠΏΠΎΡΡΠΈ Π²ΡΠ΅ ΡΠΈΠ½ΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΡ ΠΈΠΌΠ΅ΡΡ Π³ΡΠ°ΠΌΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π²ΡΡΠ°ΠΆΠ΅Π½ΠΈΡ, ΡΡΠΎ ΠΈ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ΅Ρ ΡΠΈΡΡΠ΅ΠΌΡ Π³Π»Π°Π³ΠΎΠ»ΡΠ½ΡΡ
ΡΠΎΡΠΌ, ΠΊΠ°ΠΊ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ Π² ΡΡΠ°ΡΡΠ΅, ΠΎΠΊΠ°Π·Π°Π»Π°ΡΡ ΠΏΡΠΈΠ½ΡΠΈΠΏΠΈΠ°Π»ΡΠ½ΠΎ Π²Π°ΠΆΠ½Π° Π½Π΅ ΡΠΎΠ»ΡΠΊΠΎ Π΄Π»Ρ ΡΡΡΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ. Π Π΅Π΅ Π»ΠΈΠ½Π³Π²ΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΠ·ΡΡΠΊΠ°Π½ΠΈΡΡ
ΡΠΎΠ½ΠΊΠ°Ρ ΠΈΠ½ΡΡΠΈΡΠΈΡ ΡΠΎΡΠ΅ΡΠ°Π»Π°ΡΡ Ρ ΠΎΠ³ΡΠΎΠΌΠ½ΠΎΠΉ ΠΏΠΎΠ»Π΅Π²ΠΎΠΉ ΡΠ°Π±ΠΎΡΠΎΠΉ ΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΡΠΌΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΠΌΠΈ ΠΊΠ°ΠΆΠ΄ΠΎΠ³ΠΎ Π²ΠΎΠΏΡΠΎΡΠ°. ΠΠ°ΡΡΠ½ΡΠ΅ ΡΠΎΡΠΈΠ½Π΅Π½ΠΈΡ Π£Π±ΡΡΡΠΎΠ²ΠΎΠΉ ΡΠΎΡΡΠ°Π²Π»ΡΡΡ Π·ΠΎΠ»ΠΎΡΠΎΠΉ ΡΠΎΠ½Π΄ ΡΡΡΠΊΠΎΠ»ΠΎΠ³ΠΈΠΈ
The Nomenclature of Medicinal Plants of Tuva in Dictionaries
The article introduces a list of sources which inform the reader of the plants used for medicinal purposes by Tuvan people. A brief analysis of these sources has revealed a necessity to distinguish between medicinal plants of Tuva and those used in traditional medicine of the Tuvans; and also between their names in Tuvan as the language of the indigenous people of the area, and in the language of the local Russian-speaking population, especially the Old Believers.
There is an ongoing process of mutual enrichment of the range of medicinal plants known and used by Tuvans and Russians in the region (e.g., teve-kuduruu and chuksugbai are words borrowed by the local Russians from the Tuvans; and pantseria sherstistaya or kalendula have taken the opposite route β into Tuvan from Russian). On the whole, the names for medicinal plants in various sources are absolutely stable and do not raise any doubt - such as pion, marβin koren β shengne (Eng. - peony), pikhta-choigan (Eng. - silver fir). Nevertheless, some dictionary entries may present a problem due to: a) absence of matching names in Tuvan-Russian and Russian-Tuvan dictionaries; b) difference of nomenclature for medicinal plants of Tuva in different sources; c) incongruity of descriptions leading to misunderstandings (orgaadai, smolevka/ Eng. campion); d) wrong versions of the plantβs name in translated dictionaries (khek-davan β podsnezhnik/ Eng. snowdrop instead of prostrel/eng. pasqueflower).
The authors suggest that philologists should work out a methodology of processing plant names for a future trilingual (Russian, Latin and Tuvan) dictionary of Tuvan plants of varying household significance. This methodology should then be thoroughly tested, and the dictionary should feature colour illustrations. It is thus of utter importance to have Tuvan names of plants clarified, and literary norms and their dialectal differences clearly marked in order to write up correct entries for the new dictionaries, and ultimately, to build the dictionary of Tuvan plant names on this basis
ΠΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈΠ½ΡΠ΅ΡΠΌΠΈΡΡΠΈΡΡΡΡΠ΅Π³ΠΎ ΡΠ΅ΠΆΠΈΠΌΠ° ΠΈΠ½Π³Π°Π»ΡΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΈΠ»ΠΎΠΏΡΠΎΡΡΠ° ΠΏΡΠΈ Π½Π΅ΠΎΠΏΠ΅ΡΠ°Π±Π΅Π»ΡΠ½ΠΎΠΉ Ρ ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠΎΠΌΠ±ΠΎΡΠΌΠ±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠΉ Π»Π΅Π³ΠΎΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈ
PH (pulmonary hypertension) targeted therapy may play an essential role in chronic thromboembolic pulmonary hypertension (CTEPH) patients considered inoperable. Given the limited number of PH-targeted drugs approved for CTEPH, reliable long-term data are necessary on the effects of PH-targeted drugs in patients with inoperable CTEPH. We aimed to evaluate the efficacy and safety of intermittent inhaled iloprost in inoperable CTEPH.Β Methods. The open randomized controlled trial included 22 inoperable CTEPH patients (aged (Me (25%; 75%)) 48,3 (38,4; 59,5) years; 63.6% females; 9.1% with WHO functional class (FC) IV, 72.7% with WHO-FC III, 18.2% with WHO-FC II; 6-minute walking test (6-MWT) distance of 348 (145; 443) m; mean pulmonary artery pressure (mPAP) of 41.8 (29.3; 52.8) mmHg; tricuspid annular plane systolic excursion (TAPSE) of 16.3 (14.5; 18.2) mm; plasma NT-proBNP of 853.8 (562.2; 1124.2) pg/mL). The patients were enrolled 3 β 6 months after acute pulmonary embolism and were randomized 1:1 to receive either standard therapy with vitamin K antagonists and, if indicated, oxygen and diuretics or inhaled iloprost 5.0 Β΅g / inhalation 4 times a day for 2 weeks every 3 months for 2 years in addition to the standard of care. Efficacy endpoints included changes from baseline in 6-MWT, WHO-FC, echo-parameters, inflammatory markers, time to clinical worsening, and all-cause mortality.Β Results. At baseline (prior to therapy), there were no significant differences between iloprost and control groups. Levels of C-reactive protein and the interleukin (IL)-1b, IL-6, IL-8, Ξ³-IF, and TNF-Ξ± cytokines were increased. At month 24, a mean 6-MWT distance increased by 215 m (p < 0.001) in the patients receiving inhaled iloprost and by 137 m in the control patients (p < 0.01). The control-adjusted difference was +78 m (p = 0.03). WHO-FC improved by two classes in 63.6% in iloprost group vs 0% in the control group (p = 0.028), by one class in 36.4% vs 30% (p = 0.091), and remained the same in 0% vs 70 % (p = 0.018), respectively. Inhaled iloprost delayed the time to clinical worsening (p = 0.0064). Improvements were noted in control-adjusted changes in ePASP (β18.6 mmHg; p = 0.0065), TAPSE (+2.4 mm; p = 0.028), and plasma NT-proBNP (β256.9 pg/mL; p < 0.01). The levels of inflammation decreased significantly in the iloprost group, while remained unchanged in the control group. Combination therapy with inhaled iloprost was tolerated well. One patient died in the control group (p = 0.093).Β Conclusion. Long-term intermittent inhaled iloprost for patients with inoperable CTEPH may improve their clinical status, hemodynamics, and anti-inflammatory status.Π‘ΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π»Π΅Π³ΠΎΡΠ½ΠΎΠΉ Π°ΡΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠΈ (ΠΠΠ) ΠΌΠΎΠΆΠ΅Ρ ΠΈΠ³ΡΠ°ΡΡ Π²Π°ΠΆΠ½ΡΡ ΡΠΎΠ»Ρ Ρ Π½Π΅ΠΎΠΏΠ΅ΡΠ°Π±Π΅Π»ΡΠ½ΡΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Ρ
ΡΠΎΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΠΎΠΌΠ±ΠΎΡΠΌΠ±ΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠΉ (Π₯Π’Π) Π»Π΅Π³ΠΎΡΠ½ΠΎΠΉ Π³ΠΈΠΏΠ΅ΡΡΠ΅Π½Π·ΠΈΠ΅ΠΉ (ΠΠ). Π§ΠΈΡΠ»ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ², ΠΎΡΠ½ΠΎΡΡΡΠΈΡ
ΡΡ ΠΊ ΠΠΠ-ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄ΠΎΠ²Π°Π½Π½ΡΡ
Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ Π₯Π’Π ΠΠ, ΠΎΠ³ΡΠ°Π½ΠΈΡΠ΅Π½ΠΎ, ΠΏΠΎΡΡΠΎΠΌΡ ΡΠ²Π»ΡΠ΅ΡΡΡ Π°ΠΊΡΡΠ°Π»ΡΠ½ΡΠΌ Π°Π½Π°Π»ΠΈΠ· Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΠΠΠΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² ΠΏΡΠΈ Π½Π΅ΠΎΠΏΠ΅ΡΠ°Π±Π΅Π»ΡΠ½ΠΎΠΉ Π₯Π’Π ΠΠ. Π¦Π΅Π»ΡΡ ΡΠ°Π±ΠΎΡΡ ΡΠ²ΠΈΠ»Π°ΡΡ ΠΎΡΠ΅Π½ΠΊΠ° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ ΠΈΠ½ΡΠ΅ΡΠΌΠΈΡΡΠΈΡΡΡΡΠ΅Π³ΠΎ ΡΠ΅ΠΆΠΈΠΌΠ° ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΈΠ½Π³Π°Π»ΡΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΈΠ»ΠΎΠΏΡΠΎΡΡΠ° Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π½Π΅ΠΎΠΏΠ΅ΡΠ°Π±Π΅Π»ΡΠ½ΠΎΠΉ Π₯Π’Π ΠΠ.Β ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΎΡΠΊΡΡΡΠΎΠ΅ ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ΅ ΠΊΠΎΠ½ΡΡΠΎΠ»ΠΈΡΡΠ΅ΠΌΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ Π½Π΅ΠΎΠΏΠ΅ΡΠ°Π±Π΅Π»ΡΠ½ΡΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Ρ Π₯Π’Π ΠΠ (n = 22: 63,6 % β ΠΆΠ΅Π½ΡΠΈΠ½Ρ; Π²ΠΎΠ·ΡΠ°ΡΡ β 48,3 (38,4; 59,5) Π³ΠΎΠ΄Π°; ΠΌΠ΅Π΄ΠΈΠ°Π½Π° (Me) Π²ΠΎΠ·ΡΠ°ΡΡΠ° β 25β75 %). ΠΠ IV ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠ»Π°ΡΡΠ° (Π€Π) ΠΏΠΎ ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΠΡΠ΅ΠΌΠΈΡΠ½ΠΎΠΉ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΈ Π·Π΄ΡΠ°Π²ΠΎΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΡ (ΠΠΠ) ΠΎΡΠΌΠ΅ΡΠ΅Π½Π° Ρ 9,1 % Π±ΠΎΠ»ΡΠ½ΡΡ
, III β Ρ 72,7 %, II β Ρ 18,2 %; Π΄ΠΈΡΡΠ°Π½ΡΠΈΡ ΠΏΡΠΈ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΠΈ 6-ΠΌΠΈΠ½ΡΡΠ½ΠΎΠ³ΠΎ ΡΠ°Π³ΠΎΠ²ΠΎΠ³ΠΎ ΡΠ΅ΡΡΠ° (6-ΠΠ¨Π’) ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° 348 (145; 443) ΠΌ; ΡΡΠ΅Π΄Π½Π΅Π΅ Π΄Π°Π²Π»Π΅Π½ΠΈΠ΅ Π² Π»Π΅Π³ΠΎΡΠ½ΠΎΠΉ Π°ΡΡΠ΅ΡΠΈΠΈ β 41,8 (29,3; 52,8) ΠΌΠΌ ΡΡ. ΡΡ.; ΠΏΠ»ΠΎΡΠΊΠΎΡΡΡ ΡΠΈΡΡΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠΊΡΠΊΡΡΡΠΈΠΈ ΡΡΠΈΠΊΡΡΠΏΠΈΠ΄Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΊΠΎΠ»ΡΡΠ° (ΠΠ‘ΠΠ’Π) β 16,3 (14,5; 18,2) ΠΌΠΌ; ΡΡΠΎΠ²Π΅Π½Ρ N-ΠΊΠΎΠ½ΡΠ΅Π²ΠΎΠ³ΠΎ ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠ° ΠΏΡΠ΅Π΄ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΈΠΊΠ° ΠΌΠΎΠ·Π³ΠΎΠ²ΠΎΠ³ΠΎ Π½Π°ΡΡΠΈΠΉΡΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΠ΅ΠΏΡΠΈΠ΄Π° ΠΏΠ»Π°Π·ΠΌΡ (NT-proBNP) β 853,8 (562,2; 1 124,2) ΠΏΠ³ / ΠΌΠ». Π§Π΅ΡΠ΅Π· 3β6 ΠΌΠ΅Ρ. ΠΏΠΎΡΠ»Π΅ ΠΎΡΡΡΠΎΠΉ ΡΡΠΎΠΌΠ±ΠΎΡΠΌΠ±ΠΎΠ»ΠΈΠΈ Π»Π΅Π³ΠΎΡΠ½ΠΎΠΉ Π°ΡΡΠ΅ΡΠΈΠΈ (Π’ΠΠΠ) ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Π±ΡΠ»ΠΈ ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Ρ 1 : 1 Π² 2 Π³ΡΡΠΏΠΏΡ: Π±ΠΎΠ»ΡΠ½ΡΠ΅ 1-ΠΉ Π³ΡΡΠΏΠΏΡ ΠΏΠΎΠ»ΡΡΠ°Π»ΠΈ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΡΡ ΡΠ΅ΡΠ°ΠΏΠΈΡ Π°Π½ΡΠ°Π³ΠΎΠ½ΠΈΡΡΠ°ΠΌΠΈ Π²ΠΈΡΠ°ΠΌΠΈΠ½Π° Π ΠΈ ΠΏΠΎ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΈΡΠΌ β ΠΊΠΈΡΠ»ΠΎΡΠΎΠ΄ ΠΈ Π΄ΠΈΡΡΠ΅ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΡ, 2-ΠΉ β ΠΈΠ»ΠΎΠΏΡΠΎΡΡ 5,0 ΠΌΠΊΠ³ ΠΈΠ½Π³Π°Π»ΡΡΠΈΠΎΠ½Π½ΠΎ 4 ΡΠ°Π·Π° Π² Π΄Π΅Π½Ρ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 2 Π½Π΅Π΄. ΠΊΠ°ΠΆΠ΄ΡΠ΅ 3 ΠΌΠ΅Ρ. Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 2 Π»Π΅Ρ Π² ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ ΡΠΎ ΡΡΠ°Π½Π΄Π°ΡΡΠ½ΡΠΌ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ΠΌ. ΠΡΠΈΡΠ΅ΡΠΈΡΠΌΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠ²Π»ΡΠ»ΠΈΡΡ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ Π΄ΠΈΡΡΠ°Π½ΡΠΈΠΈ ΠΏΡΠΈ Π²ΡΠΏΠΎΠ»Π½Π΅Π½ΠΈΠΈ 6-ΠΠ¨Π’, Π€Π ΠΏΠΎ ΠΠΠ, ΡΡ
ΠΎΠΊΠ°ΡΠ΄ΠΈΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΡ, Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΌΠ°ΡΠΊΠ΅ΡΡ, Π²ΡΠ΅ΠΌΡ Π΄ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΡ
ΡΠ΄ΡΠ΅Π½ΠΈΡ ΠΈ Π»Π΅ΡΠ°Π»ΡΠ½ΠΎΡΡΡ ΠΎΡ Π²ΡΠ΅Ρ
ΠΏΡΠΈΡΠΈΠ½.Β Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡΡ
ΠΎΠ΄Π½ΠΎ (Π΄ΠΎ Π½Π°ΡΠ°Π»Π° ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΠ) ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
ΡΠ°Π·Π»ΠΈΡΠΈΠΉ ΠΌΠ΅ΠΆΠ΄Ρ Π³ΡΡΠΏΠΏΠ°ΠΌΠΈ Π½Π΅ ΠΎΡΠΌΠ΅ΡΠ°Π»ΠΎΡΡ, ΠΎΠ΄Π½Π°ΠΊΠΎ Π½Π°Π±Π»ΡΠ΄Π°Π»ΠΎΡΡ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Π΅ΠΉ Π‘-ΡΠ΅Π°ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° ΠΈ ΠΏΡΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΡΠΈΡΠΎΠΊΠΈΠ½ΠΎΠ² β ΠΈΠ½ΡΠ΅ΡΠ»Π΅ΠΉΠΊΠΈΠ½Π° (IL)-1Ξ², IL-6, IL-8, ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½Π°-Ξ³ ΠΈ ΡΠ°ΠΊΡΠΎΡΠ° Π½Π΅ΠΊΡΠΎΠ·Π° ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ-Ξ±. Π§Π΅ΡΠ΅Π· 24 ΠΌΠ΅Ρ. Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
, ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
ΠΈΠ»ΠΎΠΏΡΠΎΡΡ (n = 11), ΡΡΠ΅Π΄Π½ΡΡ Π΄ΠΈΡΡΠ°Π½ΡΠΈΡ 6-ΠΠ¨Π’ ΡΠ²Π΅Π»ΠΈΡΠΈΠ»Π°ΡΡ Π½Π° 215 ΠΌ (p < 0,001); Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ (n = 11) β Π½Π° 137 ΠΌ (p < 0,01), ΠΌΠ΅ΠΆΠ³ΡΡΠΏΠΏΠΎΠ²Π°Ρ ΡΠ°Π·Π½ΠΈΡΠ° ΡΠΎΡΡΠ°Π²ΠΈΠ»Π° +78 ΠΌ (p = 0,03). Π€Π ΠΏΠΎ ΠΠΠ ΠΠ ΡΠ»ΡΡΡΠΈΠ»ΡΡ Π½Π° 2 ΠΊΠ»Π°ΡΡΠ° Ρ 63,6 % Π±ΠΎΠ»ΡΠ½ΡΡ
2-ΠΉ Π³ΡΡΠΏΠΏΡ (ΠΈΠ»ΠΎΠΏΡΠΎΡΡ) vs 0 % β Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ (p = 0,028), Π½Π° 1 ΠΊΠ»Π°ΡΡ β Ρ 36,4 % vs 30 % (p = 0,091), ΠΎΡΡΠ°Π»ΡΡ Π±Π΅Π· ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ β Ρ 0 % vs 70 % (p = 0,018) ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ. ΠΡΠΈ Π½Π°Π·Π½Π°ΡΠ΅Π½ΠΈΠΈ ΠΈΠ½Π³Π°Π»ΡΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΈΠ»ΠΎΠΏΡΠΎΡΡΠ° ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ ΡΠ²Π΅Π»ΠΈΡΠ΅Π½ΠΈΠ΅ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ Π΄ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΡ
ΡΠ΄ΡΠ΅Π½ΠΈΡ ΠΠ (p = 0,0064). Π’Π°ΠΊΠΆΠ΅ ΠΎΡΠΌΠ΅ΡΠ΅Π½Ρ ΡΠ»ΡΡΡΠ΅Π½ΠΈΡ Π² ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΡΠ°Π·Π½ΠΈΡΠ΅ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ ΡΠ°ΡΡΠ΅ΡΠ½ΠΎΠ³ΠΎ ΡΠΈΡΡΠΎΠ»ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π΄Π°Π²Π»Π΅Π½ΠΈΡ Π² Π»Π΅Π³ΠΎΡΠ½ΠΎΠΉ Π°ΡΡΠ΅ΡΠΈΠΈ (β18,6 ΠΌΠΌ ΡΡ. ΡΡ.; p = 0,0065), ΠΠ‘ΠΠ’Π (+2,4 ΠΌΠΌ; p = 0,028) ΠΈ NT-proBNP (β256,9 ΠΏΠ³ / ΠΌΠ»; p < 0,01). Π£ΡΠΎΠ²Π½ΠΈ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ Π²ΠΎΡΠΏΠ°Π»Π΅Π½ΠΈΡ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΡΠ½ΠΈΠ·ΠΈΠ»ΠΈΡΡ Ρ ΠΏΠΎΠ»ΡΡΠ°Π²ΡΠΈΡ
ΠΈΠ»ΠΎΠΏΡΠΎΡΡ ΠΈ ΠΎΡΡΠ°Π»ΠΈΡΡ Π±Π΅Π· ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ β Π² ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅. ΠΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½Π°Ρ ΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΈΠ½Π³Π°Π»ΡΡΠΈΠΎΠ½Π½ΡΠΌ ΠΈΠ»ΠΎΠΏΡΠΎΡΡΠΎΠΌ Ρ
ΠΎΡΠΎΡΠΎ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠΈΠ»Π°ΡΡ Π±ΠΎΠ»ΡΠ½ΡΠΌΠΈ. Π ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅ ΠΎΡΠΌΠ΅ΡΠ΅Π½ 1 Π»Π΅ΡΠ°Π»ΡΠ½ΡΠΉ ΠΈΡΡ
ΠΎΠ΄ (p = 0,093).Β ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΡΠΈ Π΄Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΡΠΌΠΈΡΡΠΈΡΡΡΡΠ΅ΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈΠ½Π³Π°Π»ΡΡΠΈΠΎΠ½Π½ΡΠΌ ΠΈΠ»ΠΎΠΏΡΠΎΡΡΠΎΠΌ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π₯Π’Π ΠΠ ΠΎΡΠΌΠ΅ΡΠ΅Π½ΠΎ ΡΠ»ΡΡΡΠ΅Π½ΠΈΠ΅ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈ ΠΏΡΠΎΡΠΈΠ²ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°ΡΡΡΠ° ΠΈ Π³Π΅ΠΌΠΎΠ΄ΠΈΠ½Π°ΠΌΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ
AUTOMATION OF BUSINESS PROCESSES OF A CHILDREN'S STORE WITH THE HELP OF CREATING A WEBSITE
Π Π΄Π°Π½Π½ΠΎΠΉ ΡΡΠ°ΡΡΠ΅ ΡΠ°ΡΡΠΌΠΎΡΡΠ΅Π½Π° Π°Π²ΡΠΎΠΌΠ°ΡΠΈΠ·Π°ΡΠΈΡ Π±ΠΈΠ·Π½Π΅Ρ-ΠΏΡΠΎΡΠ΅ΡΡΠΎΠ² Π½Π° ΠΏΡΠΈΠΌΠ΅ΡΠ΅ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Β«ΠΠ·ΠΎΡΠ½ΠΈΠΊΠΈΒ», Π·Π°Π½ΠΈΠΌΠ°ΡΡΠ΅Π³ΠΎΡΡ ΠΏΡΠΎΠ΄Π°ΠΆΠ΅ΠΉ Π΄Π΅ΡΡΠΊΠΈΡ
ΡΠΎΠ²Π°ΡΠΎΠ². Π ΡΠ°Π±ΠΎΡΡ Π΄Π°Π½Π½ΠΎΠ³ΠΎ ΠΌΠ°Π³Π°Π·ΠΈΠ½Π° Π±ΡΠ» Π²Π½Π΅Π΄ΡΠ΅Π½ Π²Π΅Π±-ΡΠ°ΠΉΡ. ΠΡΠ»ΠΎ Π²ΡΡΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Π΄Π°Π½Π½ΡΠΉ Π²Π΅Π±-ΡΠ°ΠΉΡ ΠΎΠΊΡΠΏΠΈΡΡΡ ΡΠ΅ΡΠ΅Π· 16 ΠΌΠ΅ΡΡΡΠ΅Π², Π° ΡΠ°ΠΊΠΆΠ΅ Π±Π»Π°Π³ΠΎΠ΄Π°ΡΡ Π°Π²ΡΠΎΠΌΠ°ΡΠΈΠ·Π°ΡΠΈΠΈ ΠΌΠ°Π³Π°Π·ΠΈΠ½ Π±ΡΠ΄Π΅Ρ ΠΈΠΌΠ΅ΡΡ ΠΊΠΎΠ½ΠΊΡΡΠ΅Π½ΡΠ½ΡΠ΅ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π° ΡΡΠ΅Π΄ΠΈ ΠΏΠΎΠ΄ΠΎΠ±Π½ΡΡ
ΠΌΠ°Π³Π°Π·ΠΈΠ½ΠΎΠ².This article discusses the automation of business processes using the example of the Ozorniki store, which sells children's goods. A website has been implemented for this shop. It was found that this website will pay off in 16 months, and also thanks to automation, the store will have a competitive advantage among similar stores
EFFICACY OF MULTIDISCIPLINARY MANAGEMENT OF PULMONARY HYPERTENSION
Aim. To assess the efficacy of regional system of multidisciplinary care in pulmonary hypertension (PH).Material andΒ methods. In aΒ single-center, pro andΒ retrospective cohortΒ study,Β 2001-2015,Β Β theΒ epidemiologicalΒ characteristicsΒ and yearly mortality from PH were assessed in the createdΒ in late 1990s multiple system of PH management in the Udmurt Republic. According to the specific drug therapy tactics, there were three periods of observation: in 2001-2005 PH patients received, by indication calcium channel blockers and supportive therapy; in 2006-2010Β sildenafil was added; from 2011 pulmonary arterial hypertension (PAH) patients also received bosentan, ambrisentan, and in chronic thromboembolic PH βinhaled iloprost.RΠ΅sults. In theΒ cardiologyΒ andΒ rheumatologyΒ clinic of theΒ Udmurt Republic, a multidisciplinary system of PH management was shaped, with three-stageΒ individualized careΒ Β ofΒ patients,Β Β beginningΒ from newbornΒ periodΒ (1stΒ Β Β stageΒ Β β pre-hospital,Β Β 2ndΒ Β Β β hospital,Β 3rdΒ Β Β β rehabilitation). WithinΒ theΒ first 5 yearsΒ of follow-up, mortality of PH patients was 15-12% per year, from 2006 to 2010 β 10-7,5% per year, in 2011-2015 β 5,6β3,8% (Ρ2015-2001=0,008).Conclusion. InterprofessionalΒ approachΒ Β toΒ PH patientsΒ careΒ in thecircumstances of regional centerΒ andΒ therapyΒ by PAH-specific drugs significantly increasedΒ survival rate of patients